See more : ITD Cementation India Limited (ITDCEM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Aerpio Pharmaceuticals, Inc. (ARPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerpio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Retal Urban Development Company (4322.SR) Income Statement Analysis – Financial Results
- Digicontent Limited (DGCONTENT.BO) Income Statement Analysis – Financial Results
- Genesis Healthcare, Inc. (GENN) Income Statement Analysis – Financial Results
- Roche Holding AG (RO.SW) Income Statement Analysis – Financial Results
- Gas Plus S.p.A. (GSP.MI) Income Statement Analysis – Financial Results
Aerpio Pharmaceuticals, Inc. (ARPO)
About Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 5.51M | 4.47M | 823.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.02M | 20.02M | 14.44M | 8.32M | 0.00 | 0.00 |
| Gross Profit | -29.51M | -15.54M | -13.62M | -8.32M | 0.00 | 0.00 |
| Gross Profit Ratio | -535.75% | -347.36% | -1,655.04% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.02M | 20.02M | 14.44M | 9.82M | 15.14M | 12.75M |
| General & Administrative | 7.44M | 8.28M | 7.97M | 8.16M | 2.52M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 1.50M | 1.40M | 1.37M |
| SG&A | 7.44M | 8.28M | 7.97M | 9.67M | 3.92M | 4.08M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 7.44M | 7.56M | 7.96M | 10.32M | 15.93M | 15.33M |
| Cost & Expenses | 42.45M | 27.57M | 22.40M | 18.64M | 15.93M | 15.33M |
| Interest Income | 29.00K | 59.00K | 600.00K | 835.00K | 768.00K | 202.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 892.00K | 1.17M | 1.11M | 1.35M | 1.35M | 1.53M |
| EBITDA | -36.05M | -22.65M | -20.47M | -16.64M | -9.54M | -13.92M |
| EBITDA Ratio | -654.58% | -506.33% | -2,487.61% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.95M | -23.82M | -21.59M | -17.99M | -10.89M | -15.46M |
| Operating Income Ratio | -670.77% | -532.45% | -2,622.96% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 29.00K | 667.00K | -594.00K | -1.49M | -5.81M | 330.00K |
| Income Before Tax | -36.92M | -23.16M | -22.18M | -19.48M | -16.70M | -15.13M |
| Income Before Tax Ratio | -670.24% | -517.55% | -2,695.14% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -36.92M | -23.16M | -22.18M | -19.48M | -16.70M | -15.13M |
| Net Income Ratio | -670.24% | -517.55% | -2,695.14% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -0.96 | -1.35 | -2.43 | -3.59 | -2.25 |
| EPS Diluted | -1.08 | -0.96 | -1.35 | -2.43 | -3.59 | -2.25 |
| Weighted Avg Shares Out | 34.29M | 24.10M | 16.42M | 7.64M | 4.65M | 6.74M |
| Weighted Avg Shares Out (Dil) | 34.29M | 24.10M | 16.42M | 8.01M | 4.65M | 6.74M |
Aerpio Pharmaceuticals Announces Reverse Merger Agreement With Aadi Bioscience
Penny Stocks to Buy in May 2021? Here's 3 Big Pre-Market Gainers
Aerpio Reports First Quarter 2021 Financial Results and Provides Business Update
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Aerpio Pharmaceuticals (ARPO) Is in Oversold Territory: What's Next?
What Makes Aerpio Pharmaceuticals, Inc. (ARPO) a New Buy Stock
Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Aerpio Pharmaceuticals' Razuprotafib Dropped From Collaborative COVID-19 Trial
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial
Aerpio (ARPO) to Report Q4 Earnings: What's in the Cards?
Source: https://incomestatements.info
Category: Stock Reports